Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edoxaban versus warfarin after initial low-molecular-weight heparin for acute symptomatic venous thromboembolism
2009-014290-40Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2009
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of edoxaban, warfarin and enoxaparin in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Symptomatic recurrent venous thromboembolism. Started Nov 2009; status: completed.
02
Drugs
edoxabanwarfarinenoxaparin
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on 2009-014290-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014290-40.